CIPLA
|
CIPLA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 65.29 | 51.05 | 34.71 | 31.19 | 29.82 |
| CEPS(Rs) | 79.22 | 64.49 | 49.65 | 44.76 | 43.02 |
| DPS(Rs) | 16.00 | 13.00 | 8.50 | 5.00 | 5.00 |
| Book NAV/Share(Rs) | 384.84 | 329.72 | 289.24 | 257.78 | 226.73 |
| Tax Rate(%) | 22.43 | 27.12 | 29.79 | 26.73 | 27.01 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.24 | 17.76 | 16.13 | 15.18 | 15.05 |
| EBIT Margin(%) | 18.58 | 16.35 | 13.41 | 12.11 | 12.22 |
| Pre Tax Margin(%) | 18.42 | 16.10 | 13.05 | 11.75 | 11.66 |
| PAT Margin (%) | 14.29 | 11.73 | 9.17 | 8.61 | 8.51 |
| Cash Profit Margin (%) | 17.27 | 14.70 | 12.95 | 12.15 | 12.29 |
| Performance Ratios | |||||
| ROA(%) | 15.36 | 13.59 | 10.19 | 9.94 | 9.95 |
| ROE(%) | 18.34 | 16.63 | 12.85 | 13.10 | 14.13 |
| ROCE(%) | 23.64 | 22.77 | 18.19 | 17.24 | 17.85 |
| Asset Turnover(x) | 1.08 | 1.16 | 1.11 | 1.15 | 1.17 |
| Sales/Fixed Asset(x) | 1.96 | 2.00 | 1.81 | 1.82 | 1.85 |
| Working Capital/Sales(x) | 2.08 | 2.50 | 2.63 | 3.03 | 3.29 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.51 | 0.50 | 0.55 | 0.55 | 0.54 |
| Receivable days | 50.64 | 45.49 | 44.13 | 42.19 | 47.44 |
| Inventory Days | 53.61 | 53.56 | 61.98 | 61.53 | 58.49 |
| Payable days | 108.56 | 103.64 | 111.52 | 98.28 | 107.95 |
| Valuation Parameters | |||||
| PER(x) | 22.08 | 29.28 | 25.95 | 32.65 | 27.34 |
| PCE(x) | 18.20 | 23.18 | 18.14 | 22.75 | 18.95 |
| Price/Book(x) | 3.75 | 4.53 | 3.11 | 3.95 | 3.60 |
| Yield(%) | 1.11 | 0.87 | 0.94 | 0.49 | 0.61 |
| EV/Net Sales(x) | 4.20 | 4.66 | 3.15 | 3.72 | 3.45 |
| EV/Core EBITDA(x) | 14.48 | 17.06 | 13.02 | 16.77 | 14.63 |
| EV/EBIT(x) | 16.81 | 20.73 | 17.27 | 22.52 | 19.16 |
| EV/CE(x) | 3.70 | 4.45 | 2.99 | 3.74 | 2.66 |
| M Cap / Sales | 4.23 | 4.68 | 3.19 | 3.78 | 3.43 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 6.88 | 13.28 | 4.55 | 13.59 | 11.84 |
| Core EBITDA Growth(%) | 13.53 | 27.90 | 13.83 | 6.98 | 27.27 |
| EBIT Growth(%) | 18.84 | 39.63 | 15.23 | 4.31 | 45.26 |
| PAT Growth(%) | 27.33 | 46.55 | 10.78 | 6.59 | 55.23 |
| EPS Growth(%) | 27.89 | 47.06 | 11.28 | 4.61 | 55.46 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.01 | 0.02 | 0.04 | 0.10 |
| Current Ratio(x) | 4.24 | 3.70 | 3.34 | 2.99 | 2.87 |
| Quick Ratio(x) | 3.21 | 2.70 | 2.31 | 1.91 | 1.85 |
| Interest Cover(x) | 111.00 | 64.44 | 37.87 | 33.85 | 21.47 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.01 | 0.03 |
Compare Financial Ratios of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹125,039.4 Cr | -0.3% | -0.9% | -3.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹384,469.0 Cr | 0.5% | -2.3% | -12.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹160,672.0 Cr | 0.9% | -0.8% | 10.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹119,542.0 Cr | -3% | -2.4% | 3.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,571.0 Cr | 0.6% | 3.9% | -0.4% | Stock Analytics | |
| MANKIND PHARMA | ₹106,634.0 Cr | -0.2% | 4.8% | 6% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -0.3% |
-0.9% |
-3.3% |
| SENSEX | 1.2% |
1.9% |
-0.2% |
You may also like the below Video Courses
